he development and commercialization of genomic-based clinical laboratory
services for cancer that allow physicians and patients to make individualized
treatment decisions. In 2004, Genomic Health launched its first test,
Oncotype DX(R), which has been shown to predict the likelihood of breast
cancer recurrence and the likelihood of chemotherapy benefit in a large
portion of early-stage breast cancer patients. The company was founded in
2000 and is located in Redwood City, California. For more information, please
visit
http://www.genomichealth.com.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score
are trademarks or registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective owners.
'/>"/>SOURCE Genomic Health, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS2.
Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics3.
Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results4.
Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation5.
Genomic Health to Present at Stephens Fall Investment Conference6.
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated7.
NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 108.
Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference9.
/C O R R E C T I O N -- Rosetta Genomics Ltd/10.
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress11.
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference